The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone in the company’s transition ...

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

Genes involved in the regulation of cell division, movement and signalling for example can function as oncogenes under specific conditions. Although enhancing the GTPase activity of KRAS is an ...

Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced ...

KRAS driver mutations are found in greater than ... alteration-specific therapeutics to address high-value and validated oncogenic drivers. Our pipeline includes two Phase 1 therapies in ...

Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...

Researchers shed new light on G-quadruplexes, a type of secondary DNA structure that has attracted attention as a potential therapeutic target in cancer.

Every day, billions of cells in your body divide, helping to replace old and injured cells with new ones. And each time this ...

We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...